[go: up one dir, main page]

MX2018000218A - Composiciones farmaceuticas solidas para el tratamiento del vhc. - Google Patents

Composiciones farmaceuticas solidas para el tratamiento del vhc.

Info

Publication number
MX2018000218A
MX2018000218A MX2018000218A MX2018000218A MX2018000218A MX 2018000218 A MX2018000218 A MX 2018000218A MX 2018000218 A MX2018000218 A MX 2018000218A MX 2018000218 A MX2018000218 A MX 2018000218A MX 2018000218 A MX2018000218 A MX 2018000218A
Authority
MX
Mexico
Prior art keywords
solid pharmaceutical
pharmaceutical compositions
compound
pharmaceutically acceptable
treating hcv
Prior art date
Application number
MX2018000218A
Other languages
English (en)
Inventor
Gao Yi
Kyeremateng Samuel
Mueller Thomas
Westedt Ulrich
Lander Ute
Tong Ping
Sever Nancy
Steitz Benedikt
Reul Regina
Obermiller Constanze
Jayasankar Adivaraha
Simon Michael
Hach Harald
Schneider Katrin
Asmus Katharina
Zhu Donghua
Naris Marius
Garrett Colleen
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2018000218A publication Critical patent/MX2018000218A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención presenta composiciones farmacéuticas sólidas que comprenden el Compuesto 1 y el Compuesto 2. En una realización, la composición farmacéutica sólida incluye (1) una primera capa que comprende 100 mg de Compuesto 1, así como un polímero hidrófilo farmacéuticamente aceptable y un tensioactivo farmacéuticamente aceptable, todos los cuales están formulados en dispersión sólida amorfa; y (2) una segunda capa que comprende 40 mg de Compuesto 2, así como un polímero hidrófilo farmacéuticamente aceptable y un tensioactivo farmacéuticamente aceptable, todos los cuales están formulados en una dispersión sólida amorfa.
MX2018000218A 2015-06-26 2016-06-24 Composiciones farmaceuticas solidas para el tratamiento del vhc. MX2018000218A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562185145P 2015-06-26 2015-06-26
US201562186154P 2015-06-29 2015-06-29
US201562193639P 2015-07-17 2015-07-17
US201662295309P 2016-02-15 2016-02-15
PCT/US2016/039266 WO2016210273A1 (en) 2015-06-26 2016-06-24 Solid pharmaceutical compositions for treating hcv

Publications (1)

Publication Number Publication Date
MX2018000218A true MX2018000218A (es) 2018-03-08

Family

ID=56409187

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000218A MX2018000218A (es) 2015-06-26 2016-06-24 Composiciones farmaceuticas solidas para el tratamiento del vhc.

Country Status (24)

Country Link
US (3) US20160375087A1 (es)
EP (1) EP3313378A1 (es)
JP (2) JP7162425B2 (es)
KR (1) KR102637828B1 (es)
CN (1) CN107920996A (es)
AU (1) AU2016283018C1 (es)
BR (1) BR112017028185A2 (es)
CA (1) CA2990855A1 (es)
CL (1) CL2017003350A1 (es)
CO (1) CO2017013305A2 (es)
CR (1) CR20180030A (es)
DO (1) DOP2017000314A (es)
EA (1) EA201890160A1 (es)
EC (1) ECSP18000689A (es)
HK (1) HK1250627A1 (es)
IL (1) IL256504B (es)
MX (1) MX2018000218A (es)
MY (1) MY192606A (es)
PE (1) PE20180488A1 (es)
PH (1) PH12017502426A1 (es)
RU (2) RU2021102950A (es)
SG (1) SG10202002899VA (es)
WO (1) WO2016210273A1 (es)
ZA (1) ZA201800533B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
HK1255203A1 (zh) * 2015-07-17 2019-08-09 Abbvie Inc. 用於治疗hcv的固体药物组合物
GB202113944D0 (en) * 2021-09-29 2021-11-10 Univ Liverpool Injectable formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
DE102004008804A1 (de) 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
ES2300188B1 (es) 2006-05-24 2009-05-01 Ferrer Internacional, S.A. Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
EP2853531A3 (en) * 2009-06-11 2015-08-12 AbbVie Bahamas Ltd. Antiviral compounds
US8716454B2 (en) * 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
PL2498758T3 (pl) 2009-11-13 2019-02-28 Astrazeneca Ab Formulacje tabletek dwuwarstwowych
NZ605440A (en) * 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
NZ608720A (en) * 2010-09-21 2015-03-27 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
LT2897611T (lt) 2012-09-18 2019-12-10 Abbvie Inc Hepatito c gydymo būdai
RS60881B1 (sr) * 2013-03-14 2020-11-30 Abbvie Inc Kombinacija dva antivirusa za lečenje hepatitisa c

Also Published As

Publication number Publication date
EP3313378A1 (en) 2018-05-02
HK1250627A1 (zh) 2019-01-11
IL256504A (en) 2018-02-28
JP7162425B2 (ja) 2022-10-28
RU2018102809A (ru) 2019-07-29
SG10202002899VA (en) 2020-05-28
ECSP18000689A (es) 2018-03-31
PH12017502426A1 (en) 2018-07-02
CO2017013305A2 (es) 2018-05-21
AU2016283018B2 (en) 2021-10-07
CL2017003350A1 (es) 2018-06-22
US20160375087A1 (en) 2016-12-29
AU2016283018C1 (en) 2022-03-03
JP2018518517A (ja) 2018-07-12
RU2018102809A3 (es) 2019-12-10
KR102637828B1 (ko) 2024-02-20
EA201890160A1 (ru) 2018-06-29
ZA201800533B (en) 2018-12-19
IL256504B (en) 2021-09-30
JP2022177014A (ja) 2022-11-30
WO2016210273A1 (en) 2016-12-29
MY192606A (en) 2022-08-29
AU2016283018A1 (en) 2018-01-25
CN107920996A (zh) 2018-04-17
PE20180488A1 (es) 2018-03-07
NZ738746A (en) 2024-10-25
CA2990855A1 (en) 2016-12-29
KR20180021840A (ko) 2018-03-05
US20190216882A1 (en) 2019-07-18
DOP2017000314A (es) 2018-02-15
US20200282004A1 (en) 2020-09-10
RU2021102950A (ru) 2021-03-01
BR112017028185A2 (pt) 2018-09-04
CR20180030A (es) 2018-05-24

Similar Documents

Publication Publication Date Title
WO2016137235A3 (ko) 마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물
MX2020007797A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
HK1255162A1 (zh) 爱帕琳肽受体激动剂及使用方法
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
WO2018107155A8 (en) SUL-RICH AND N-H-FREE PERHYDRIDOPOLYSILZANE COMPOSITIONS, SYNTHESIS AND USES THEREOF
HK1254608A1 (zh) 改良的地拉罗司制剂及其制备方法
MX2024010625A (es) Compuestos antibioticos, metodos de fabricacion de los mismos, composiciones farmaceuticas conteniendo los mismos y usos de los mismos.
ZA201807446B (en) Improved drug formulations
PH12017502426A1 (en) Solid pharmaceutical compositions for treating hcv
MX2013011159A (es) Obras en suelo reforzado.
PH12018500132A1 (en) Solid pharmaceutical compositions for treating hcv
WO2018144870A8 (en) Compositions and methods for inhibiting reticulon 4
MX2018014790A (es) Formulacion combinada de tres compuestos antivirales.
WO2015073177A8 (en) Vaginal inserted estradiol pharmaceutical compositons and methods
WO2014145126A3 (en) Methods of treating dyskinesia and related disorders
MX2019001771A (es) Composición farmacéutica sólida que comprende el sofosbuvir amorfo.
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
WO2019070709A8 (en) Compounds for treating or preventing flavivirus infections
MX2021012320A (es) Composiciones farmaceuticas solidas para el tratamiento del hcv.
MX2018005134A (es) Formulacion de factor viii (fviii).
WO2019190427A3 (en) The immediate release combination comprising raloxifene and at least one antipsychotic agent
WO2018024888A8 (en) Compositions and the use thereof for treating or preventing rosacea
WO2019190435A3 (en) The combination comprising adapalene, benzoyl peroxide and an agent from the cicatrizant group
UA91708U (uk) Антибактеріальна композиція
HK1247094A1 (zh) 治療上皮樣細胞腫瘤的方法